2012 Annual Paris Melanoma Conference
Marriott Rive Gauche
Hotel and Conference Centre 17 Boulevard Saint Jacques Paris, 75014 France
Paris, France
On behalf of the Scientific Committee, we are pleased to invite you to 2012 Annual Paris Melanoma Conference, to be held in Paris on 27 – 28 April 2012.

This conference will provide a highly interactive forum in which leading experts and clinical researchers in the field of melanoma can discuss recent advances in clinical trial data and scientific research. This blend of clinical and scientific research with clinical practice will offer the unique opportunity for participants to be updated on all aspects of melanoma research. Oral presentations and poster sessions will highlight important developments in the field, including emerging therapies and implementation of new treatment strategies. We are certain you will gain valuable insight into the current status of preclinical melanoma research and the application of new trial data into clinical practice to ultimately improve patient care.

Additionally, the 2012 Annual Paris Melanoma Conference is preceded by the EORTC Melanoma Group Meeting, held on Thursday, 26 April 2012. We hope that you will enjoy the beauty and culture of Paris.

We look forward to welcoming you to the 2012 Annual Paris Melanoma Conference.

Most EU citizens only need their national identity card or passport to enter France. Non-EU citizens require a valid passport to enter France, but many countries are exempt from tourist visas. It is essential that you check with the French embassy or consulate in your country before travelling. Without exception, passports must be valid for at least six months after your planned date of departure from France.

prIME Oncology will not directly contact embassies and consulates on behalf of applicants. It is the sole responsibility of the delegates to look after their visa requirements.

Note: Passport and visa requirements are liable to change at short notice.  Travelers are advised to check their entry requirements with their embassy or consulate.


Schedule of Presentations:

Friday, April 27, 2012
08:30:00 Opening Presentation: An Era of New Challenges in Melanoma Alexander M. M. Eggermont
08:55:00 SESSION I | Emerging Data in Epidemiology, Genetics, and Prevention of Melanoma Brigitte Bressac-de Paillerets
09:00:00 The melanoma screening debate Philippe Autier
09:25:00 Microphthalmia-associated transcription factor (MITF) in melanoma Brigitte Bressac-de Paillerets
09:50:00 Break and poster viewing
10:30:00 Recent (epi)genetic findings in melanoma Julia Newton-Bishop
10:55:00 Oncogene-induced senescence and melanoma
11:15:00 SESSION II | New Diagnostic Strategies and Classification Systems for Melanoma Alessandro Testori
11:20:00 Molecular classification systems: Merge or purge? Alan Spatz
11:45:00 Sentinel node biopsy: Lessons from a European - Australian comparison
12:30:00 Satellite Lunch Symposium
14:15:00 SESSION III | Advances in Immunotherapy for Melanoma Jeffrey Weber
14:20:00 Presentation TBD
14:45:00 Immunogenic cell death: The new strategic paradigm Laurence Zitvogel
15:10:00 An update on ipilimumab combination studies Jedd D. Wolchok
15:35:00 New data on studies targeting PD-1 Jeffrey Weber
16:00:00 Adoptive T-cell programs: New strategies John B.A.G. Haanen
16:25:00 Break and poster viewing
17:00:00 SESSION IV | Oral Presentation of Best Abstracts and Poster Awards Richard Marais
Saturday, April 28, 2012
08:55:00 SESSION V | New Preclinical Models Richard Marais
09:00:00 Elucidating immunomodulation | New murine melanoma models Antoni Ribas
09:25:00 New melanoma metastasis model in zebrafish Reinhard Dummer
09:50:00 Break and poster viewing
10:15:00 SESSION VI | Evaluating and Implementing New Therapeutic Strategies in Melanoma Management Laurence Zitvogel
10:20:00 Update on ipilimumab in the adjuvant setting Jeffrey Weber
10:45:00 BRAF + MEK combinations and treatment flow diagrams Richard Kefford
11:15:00 Presentation TBD
12:00:00 Satellite Lunch Symposium
13:40:00 SESSION VII | Molecular Pathways and Applications in Basal Cell Carcinoma and Merkel Tumors Antoni Ribas
13:45:00 Evolving clinical paradigms for the management of BCC Dirk Schadendorf
14:10:00 Merkel cell carcinoma: Do we know what to target? Jürgen Becker
14:35:00 Break and poster viewing
15:00:00 SESSION VIII | New Questions and New Clinical Trial Designs Alexander M. M. Eggermont
15:05:00 New targeted agents for melanoma: BRAF and beyond Richard Kefford
15:30:00 Complexity of cross-talk resistance Richard Marais
15:55:00 Importance of AKT/MTOR pathway involvement Antoni Ribas
16:20:00 Ocular melanoma: Current status and new perspectives Sophie Piperno-Neumann
16:45:00 Concluding remarks: Tackling the next hurdles
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.